GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM ...

Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc ), a neonatal Fc receptor blocker, ...

The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

The CDC reported that COVID vaccines reduced the risk of ER visits by 76% in kids under age 4 and by 56% in kids ages 5 to 17 during the first 6 months after vaccination. (HealthDay News) — COVID-19 ...

The pivotal phase 3 RINGSIDE trial investigated varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors.

Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Lerochol is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...

Daybue Stix, a strawberry-flavored trofinetide powder mixable with water-based liquids, gains FDA approval for Rett syndrome treatment.

HealthDay News — Federal officials say the US Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and children following COVID-19 vaccination. Federal officials say ...